Emerging therapeutic strategies for the management of dyslipidemia in patients with the metabolic syndrome.
The benefits of lipid-lowering therapy in significantly reducing cardiovascular events has been established in many at-risk populations. However, patients with the metabolic syndrome (MS) pose a challenge for clinical management. A high degree of residual risk exists in patients with the MS or diabetes mellitus, and this is of growing importance because of the increasing prevalence of obesity and its associated comorbidities in the world. As the MS has emerged as a major risk factor for both cardiovascular disease and diabetes, targeting treatment to achieve aggressive goals becomes paramount. This article reviews emerging therapeutic strategies for the management of dyslipidemia in patients with the MS.
Davidson
Michael H
MH
Radiant Research, Chicago, Illinois, USA. michaeldavidson@radiantreasearch.com
D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D008076:Cholesterol, HDL / Q000032:analysis / Q000187:drug effects; D008078:Cholesterol, LDL / Q000032:analysis / Q000187:drug effects; D015897:Comorbidity; D003324:Coronary Artery Disease / Q000517:prevention & control*; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology*; D008297:Male; D024821:Metabolic Syndrome / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology*; D008875:Middle Aged; D015995:Prevalence; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012720:Severity of Illness Index; D015996:Survival Rate; D016896:Treatment Outcome
D000924:Anticholesteremic Agents; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL